Actos on a good-news roll

The EU's drug committee also gave the go-ahead for a new combo pill that melds the diabetes remedy Actos with old blood-sugar standby metformin. This thumbs-up follows a spate of good news for Actos, including a new study unveiled Wednesday that showed it controlled blood sugar and lipid levels better than Avandia did. Another study, presented at the same meeting of the European Association for the Study of Diabetes, showed that Actos cut heart attack risk by 38 percent.

- check out this EMEA release on the Actos combo drug
- and this release on the Actos studies

Related Articles:
Actos study points to reduction in heart attacks, strokes. Report
Diabetes drug helps reduce rate of strokes. Report
Avandia risks back in the headlines. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.